The Role of Genetic Factors in the Pathogenesis of Small Vessel Vasculitis

Anastasia Francesca^*
*Correspondence: Anastasia Francesca, Department of Medicine, Brandon University, 270 18th St, Brandon, MB R7A 6A9, Canada, Email:

Introduction

Small vessel vasculitis encompasses a range of conditions, including Wegener's granulomatosis (now known as granulomatosis with polyangiitis), microscopic polyangiitis and Churg-Strauss syndrome. The precise etiology of SVV remains largely unclear, but genetic predisposition has emerged as a crucial factor. This article reviews the role of genetic factors in SVV, exploring specific genetic variants, their functional implications and potential pathways through which they influence disease development. The Human Leukocyte Antigen (HLA) genes are a crucial component of the immune system, playing a significant role in the pathogenesis of Small Vessel Vasculitis (SVV). These genes encode proteins that are essential for the immune system's ability to differentiate between self and non-self, thus influencing immune responses and susceptibility to various diseases, including SVV.

HLA genes are highly polymorphic, meaning they have many different alleles that can vary between individuals. The most studied HLA genes in the context of SVV are HLA-DRB1, HLA-DPB1 and HLA-B. Variants in these genes have been associated with an increased risk of developing small vessel vasculitis. For instance, specific alleles of HLA-DRB1, such as HLADRB1* 04:01, have been linked to Ganulomatosis with Polyangiitis (GPA). The presence of this allele is believed to increase susceptibility to GPA by influencing antigen presentation to T-cells. The mechanisms by which HLA variants contribute to SVV involve alterations in the immune system's antigenpresenting processes. HLA molecules present peptide fragments derived from proteins to T-cells. If the peptides presented by certain HLA molecules are perceived as foreign or abnormal, this can lead to an inappropriate immune response. In SVV, this inappropriate response can target the small blood vessels, leading to inflammation and damage. Additionally, the interaction between HLA molecules and autoantigens is crucial. In some cases, HLA variants may influence the likelihood of developing autoantibodies that target components of small blood vessels. For example, in ANCA-associated vasculitis, the presence of certain HLA alleles may be linked to the production of Anti-neutrophil Cytoplasmic Antibodies (ANCA), which are implicated in the disease's pathogenesis.

Description

The functional consequences of HLA gene variants in SVV are complex and involve a combination of genetic, environmental and immunological factors. Variants in HLA genes can affect the specificity and strength of immune responses, potentially leading to an increased risk of developing SVV in individuals who carry these genetic markers. Understanding the role of HLA genes in SVV provides valuable insights into the genetic basis of the disease and may help in identifying individuals at higher risk. It also underscores the importance of HLA typing in diagnosing and managing SVV, as well as in developing targeted therapies that could modulate the immune response associated with these genetic variants.

PR3 (proteinase 3) and MPO (Myeloperoxidase) are enzymes produced by neutrophils and they play a central role in the pathogenesis of ANCA (antineutrophil cytoplasmic antibody)-associated vasculitis, a type of small vessel vasculitis. ANCA-associated vasculitis includes conditions such as Granulomatosis with Polyangiitis (GPA), microscopic polyangiitis (MPA) and Eosinophilic Granulomatosis with Polyangiitis (EGPA). In these diseases, the presence of ANCA against PR3 or MPO is a key feature. PR3-ANCA and MPOANCA are autoantibodies that target the respective enzymes PR3 and MPO, leading to inflammation and damage in small blood vessels. The production of these autoantibodies is thought to be driven by a combination of genetic predisposition, environmental factors and immune system dysregulation [1,2].

The role of PR3 and MPO in ANCA-associated vasculitis begins with their expression on the surface of neutrophils. PR3 is a serine protease found in the granules of neutrophils, while MPO is an enzyme involved in the production of reactive oxygen species and is also found in neutrophil granules. When these enzymes are released into the bloodstream, they can form complexes with circulating antibodies, which are then recognized by the immune system as foreign. The binding of ANCA to PR3 or MPO on neutrophils triggers a series of inflammatory responses. This interaction activates neutrophils, leading to the release of inflammatory mediators and reactive oxygen species. The inflammatory response causes damage to the endothelial cells lining small blood vessels, resulting in vasculitis. The immune complexes formed by the PR3 or MPO and ANCA can deposit in various tissues, leading to localized inflammation and tissue damage characteristic of ANCA-associated vasculitis.

Genetic factors also contribute to the susceptibility of developing ANCA-associated vasculitis. Variants in genes encoding PR3 and MPO can influence the production of these enzymes and their interaction with ANCA. For example, certain genetic polymorphisms in the PR3 gene can affect the antigenicity of PR3, potentially increasing the likelihood of an autoimmune response. PR3 and MPO play critical roles in the pathogenesis of ANCAassociated vasculitis by serving as targets for autoantibodies that lead to neutrophil activation and subsequent inflammation of small blood vessels. The interplay between genetic factors, environmental triggers and immune system dysregulation underlies the development and progression of these diseases. Understanding these mechanisms provides insights into the disease process and may help in developing targeted therapies for ANCA-associated vasculitis [3,4].

Genetic variants in inflammatory pathways significantly influence the susceptibility and progression of Small Vessel Vasculitis (SVV). These pathways are crucial for regulating immune responses and maintaining homeostasis and genetic alterations in key genes can lead to dysregulation, resulting in excessive inflammation and tissue damage characteristic of SVV. One of the primary inflammatory pathways involved is the Tumor Necrosis Factor-alpha (TNF-α) pathway. TNF-α is a cytokine that plays a central role in inflammation and immune response. Genetic variants in the TNF-α gene can affect the levels and activity of this cytokine. For instance, polymorphisms in the promoter region of the TNF-α gene can lead to increased production of TNF-α, which in turn can exacerbate inflammatory processes and contribute to the development of SVV. Elevated TNF-α levels have been associated with severe disease manifestations and may influence the response to treatment in SVV patients.

Interleukin-6 (IL-6) is another key cytokine involved in inflammation and genetic variants in the IL-6 gene can impact its expression and function. IL-6 is involved in the acute-phase response and the activation of inflammatory pathways. Variants that lead to increased IL-6 production can enhance the inflammatory response and contribute to the pathogenesis of SVV. IL-6 polymorphisms have been associated with disease severity and progression, highlighting their role in modulating the inflammatory landscape in SVV. Genetic variations in genes encoding for Pattern Recognition Receptors (PRRs), such as Toll-like Receptors (TLRs), also play a role in inflammatory responses. TLRs are involved in recognizing Pathogen-associated Molecular Patterns (PAMPs) and Damage-Associated Molecular Patterns (DAMPs), initiating innate immune responses. Variants in TLR genes can alter their function and affect the ability to detect and respond to inflammatory stimuli.

Altered immune responses play a central role in the development and progression of Small Vessel Vasculitis (SVV). The immune system's primary function is to protect the body from infections and harmful substances, but when it becomes dysregulated, it can mistakenly target and damage the body's own tissues, leading to inflammatory diseases like SVV. In SVV, immune system abnormalities often manifest as inappropriate or excessive immune responses against self-antigens, which can result in chronic inflammation and damage to small blood vessels. This inappropriate immune activation is typically characterized by the production of autoantibodies and the activation of immune cells that attack the body's own tissues.

One of the critical features of altered immune responses in SVV is the production of autoantibodies, such as Antineutrophil Cytoplasmic Antibodies (ANCA). ANCA are directed against specific proteins in neutrophils, such as Proteinase 3 (PR3) and Myeloperoxidase (MPO). The presence of these autoantibodies leads to the activation of neutrophils and the release of inflammatory mediators, which contribute to endothelial cell damage and vasculitis. The formation of immune complexes between ANCA and their target antigens can exacerbate inflammation and cause further damage to small vessels. Another aspect of altered immune responses in SVV involves the dysregulation of T-cell responses. T-cells are crucial for recognizing and responding to pathogens and damaged cells. In SVV, T-cells may become activated inappropriately, leading to the production of inflammatory cytokines and the recruitment of other immune cells to sites of inflammation. This aberrant T-cell activation can result in the sustained inflammatory response seen in SVV [5].

Conclusion

Genetic factors play a crucial role in the pathogenesis of small vessel vasculitis. Identifying and understanding these factors can enhance diagnostic accuracy, enable personalized treatment approaches and contribute to better disease management. Continued research into the genetic underpinnings of SVV holds promise for improving patient outcomes and advancing our knowledge of these complex disorders. Overall, genetic variants in inflammatory pathways can lead to alterations in cytokine production, immune responses and the regulation of inflammation, all of which are crucial in the pathogenesis of small vessel vasculitis. These variants may enhance the inflammatory response, leading to the damage of small blood vessels and the clinical manifestations of SVV. Understanding these genetic factors provides insights into the underlying mechanisms of SVV and can inform the development of targeted therapies aimed at modulating inflammatory pathways to improve disease outcomes.

Acknowledgement

None.

Conflict of Interest

Authors declare no conflict of interest.

References

1. Prabhahar, Arun, G. S. R. S. N. K. Naidu and Prabhat Chauhan, et al. "ANCA-associated vasculitis following ChAdOx1 nCoV19 vaccination: Case-based review."Rheumatol Int 42 (2022):749-758.

   Google Scholar, Crossref, Indexed at

2. Yadav, Rukesh, Sangam Shah and Santosh Chhetri. "ANCA-associated vasculitis following Johnson and Johnson COVID-19 vaccine."Ann Med Surg79 (2022):104123.

   Google Scholar, Crossref, Indexed at

3. Zamoner, Welder, Julia Baldon Scardini, Bruna Jordana De Dio and Amanda de Melo Marques, et al. "ANCA-associated vasculitis following Oxford-AstraZeneca COVID-19 vaccine in Brazil: Is there a causal relationship? A case report."Fron Med 9(2022):1003332.

   Google Scholar, Crossref, Indexed at

4. Saiz, Luis Carlos and María Villanueva Alcojol. "Case report: Granulomatosis with polyangiitis (GPA) and facial paralysis after COVID-19 vaccination." Med Clín 161 (2023): 84-85.

   Google Scholar, Crossref, Indexed at

5. Prema, Jansi, Aarthi Muthukumaran and Nived Haridas, et al. "Two cases of double-positive antineutrophil cytoplasmic autoantibody and antiglomerular basement membrane disease after BBV152/Covaxin vaccination."Kidney Int Rep 6 (2021): 3090-3091.

   Google Scholar, Crossref, Indexed at